Table 2.

The rate of antibiotics susceptibility among MDR-GNB isolates collected in 2017 and 2018, by Al Hamdan et al. (2022).

% Susceptibility
Species	Year	AMIK	AMP	AMC/CLV	CZO	FEB	CAZ	CRO	CXM	CIP	LEVO	GENT	IMP	MRP	NFN	PIP/TAZ	TRIMETH
E. coli	2017	91	6	22	11	43		35	34	70	40	87	99	99	51	40	49
	2018	71	24	53	50	52		50	49	62	84	97	96	61	63	72	47
Klebsiella spp.	2017	84		35	35	48		44	43	82	75	76	99	99	30	68	61
	2018	96		16	45	43		42	42	78	90	97	97	79	21	56	60
Proteus spp.	2017	79	4	34	36	51		45	41	93	87	64	62	62		42	47
	2018	93	29	28	25	45*		39	30	89	68	61	30	89		36	59
Enterobacter spp.	2017	71	0	0	0	29		21	0	93	93	70	100	100		29	0
	2018	94	0	0	0	56		41	0	91	88	85	74	91		47	71
Acinetobacter spp.	2017	42				10	3			14	16	29	13	13		6	19
	2018	82				59	59			76	82	71	71	76		47	88
Pseudomonas spp.	2017	81				29	29			79	90	76	48	47		29
	2018	96				50	49			85	94	67	70	85		39

%Susceptibility rate = Number of susceptible isolates/Total number of isolates × 100. Boxes in green, yellow, and red color reflect susceptibility rate of: 90–100, 70–89, and <70%, respectively. AMIK, Amikacin; AMP, Ampicillin; AMC/CLAV, Amoxicillin/clavulanic acid; CZO, Cefazolin; FEB, Cefepime; CAZ, Ceftazidime; CRO, Ceftriaxone; CXM, Cefuroxime; CIP, Ciprofloxacin; LEVO, Levofloxacin; GENT, Gentamicin; IMP, Mipenem; MRP, Meropenem; NFN, Nitrofurantoin; TAZ, Piperacillin/tazobactam; and TRIMETH, Trimethoprim. Reprinted from Table 1 in “Evaluating the prevalence and the risk factors of Gram-negative multi-drug resistant bacteria in eastern Saudi Arabia” by Al Hamdan et al. (2022), licensed under Creative Commons Attribution (CC BY NC) license (https://creativecommons.org/licenses/by/4.0/).